Skip to main content
Main analysis: SaverOne: The Defense Option Opened, But Dilution Still Runs The Story
ByMarch 28, 2026~10 min read

SaverOne And VisionWave: The Strategic Value Opened, But Who Really Captures It?

The main article showed that the VisionWave deal opened a real defense-facing lane for SaverOne, but it did not settle who actually captures the value. This follow-up shows that out of a potential package of up to $10 million, at least $3.5 million is earmarked for the RF platform and up to another $3 million can flow directly to management before full commercial rights and final control are in place.

The main article already established that the VisionWave transaction opened a real strategic option for SaverOne in defense, but it did not automatically solve the shareholder-economics question. This follow-up isolates the contract itself: who gets the stock, when control starts to move, and how much of the new value actually remains at the public-company layer.

The easy headline is $7 million. The correct reading is broader: up to $7 million of VisionWave stock for SaverOne, up to another $3 million of VisionWave stock for management, the right to appoint as many as three board designees, and a requirement that at least half of the economic value received at the company level be used for the RF platform under a jointly monitored budget. So this is not only a cooperation agreement. It is a platform-build, value-allocation, and control-shift structure at the same time.

The Headline Is $7 Million, But The Economic Design Reaches Up To $10 Million

The package opens in three layers, not as one clean company-level payment

The $7 million figure describes only the consideration that goes to the company itself. Under the agreement, VisionWave may reach roughly 51% of SaverOne in exchange for aggregate VisionWave equity worth $7 million, in three steps: a first 19.99% block, a second 19.99% block upon Milestone 1, and an additional 11.02% block upon Milestone 2.

But the deal does not stop there. In parallel with the transaction, and as "additional consideration", VisionWave committed to grant SaverOne management equity awards with aggregate value of up to $3 million under its own equity plan. The schedule attached to the agreement sets the target allocation at 50% to Ori Gilboa and 50% to Jacob Tenenboim, while also allowing reallocation and additional participation by other officers. That means that, even in the base design, as much as 30% of the total package can bypass the public-company layer altogether.

And this is not theoretical. On March 5, 2026, when Stage 1 closed, VisionWave issued SaverOne 365,610 restricted VisionWave shares worth about $2.74 million, based on a five-day VWAP of $7.5031 per share. On that same stage, Ori Gilboa and Jacob Tenenboim each received 78,343 restricted VisionWave shares directly. Combined, that was about $1.18 million of direct management equity.

This is the center of the continuation thesis. At the Stage 1 level, the package that already opened totals about $3.92 million. Roughly 30% of that went directly to the CEO and chairman. And before even looking at that split, at least half of the value received by the company itself must be directed into development, commercialization, and operation of the RF platform. So at the Stage 1 level, the direct equity granted to the CEO and chairman is already close to the maximum value that can remain flexible at the company level.

LayerAmountWho receives itWhat constrains it
Company-level stock consideration across the full transactionUp to $7.0 millionSaverOneIt is VisionWave stock, not cash, and at least 50% of the economic value is already earmarked for the RF platform
Management equity grantsUp to $3.0 millionSaverOne managementMilestone vesting, performance conditions, transfer restrictions, and clawback provisions
Minimum earmarked layer at the company levelAt least $3.5 millionThe RF platformJoint budget, joint oversight, quarterly reporting
Maximum flexible layer at the company levelUp to $3.5 millionSaverOneOnly after taking into account the mandatory RF use and the fact that this is external stock whose usefulness still depends on registration and market price

The message is straightforward: the value that opened does not sit in one place. Some of it is at the company, some of it is pre-committed, and some of it goes directly to management.

Stage 1 Already Paid In Equity, But Full Commercial Rights Are Still Ahead

The second point that is easy to miss is that the first equity block was not paid against a finished defense product or full commercial rights. The agreement gives SaverOne a worldwide, royalty-free license to use VisionWave RF technologies, but it states explicitly that, from the effective date, the license is only effective for initial access, evaluation, and limited integration work. It becomes fully operational only upon Milestone 1.

In other words, on March 5, 2026, SaverOne had already entered the dilution of Stage 1, but the full operating value of the transaction had not yet been proven. That does not necessarily make the structure wrong. Platform-build deals often work exactly this way: equity and access first, integration second, commercialization only afterward. But for common shareholders the implication is critical: Stage 1 bought time and access, not a proven defense product.

The timing is also fairly tight. VisionWave may terminate the agreement if Milestone 1 is not achieved within 12 months of the effective date, or if Milestone 2 is not achieved within 12 months of the prior closing. So the transaction is built as a proof clock, not as an open-ended strategic affiliation.

The idea that the deal solves funding is also too generous. In 2025 SaverOne used NIS 29.207 million, about $9.156 million, in operating cash flow, and it ended the year with only NIS 14.144 million of cash, about $4.4 million. Even the entire $7 million company-level consideration is smaller than that annual operating cash burn, and at least half of it is already earmarked. So even if the transaction advances exactly as planned, this is still not a clean replacement of capital markets with a self-funding platform. It is a strategic option that adds another route, not a balance-sheet reset.

There is one more asymmetry that matters. If VisionWave's share price drops by more than 10% from the VWAP set for a given stage during the ten trading days after issuance, VisionWave has to make up the shortfall through additional stock or pre-funded warrants. That protection does not apply only to the company's stock consideration. Schedule 1.7 states explicitly that the management grants enjoy the same protections, rights, and privileges. Common shareholders who absorb the dilution do not receive a parallel protection mechanism.

Control Does Not Arrive All At Once, But Governance Influence Starts Early

Equity blocks open in stages, and board rights arrive with each closing

The easy way to read the transaction is to focus only on the destination, roughly 51% for the eventual controlling party. But the economics of control are built earlier and in layers.

At the equity level, VisionWave receives a block at each stage. At the governance level, SaverOne agreed that from each closing date, and for as long as VisionWave owns at least 10% of SaverOne, it will use best efforts to let VisionWave designate one individual for each completed stage, up to three designees in total. The current board has five members, and the company undertook to expand it if needed to accommodate those designees.

That is not all. The agreement also requires SaverOne to use reasonable best efforts to place VisionWave designees on the relevant board committees, including audit, compensation, and nominating committees, subject to independence and qualification rules. So VisionWave's influence does not wait for the final ownership outcome. It starts to build through board seats, committees, and information rights along the way.

That is where the mandatory use-of-proceeds clause becomes more important. At least 50% of the economic value realized from the VisionWave shares, or from their sale, has to go into developing, commercializing, and operating the RF platform. The budget is meant to be set within 30 days of Stage 1, updated quarterly, and monitored through quarterly reports certified by the chief financial officer. This is no passive portfolio investment. It is a structure in which the party moving toward control also gets a built-in path to monitor and influence how a large share of the consideration is spent.

From the ordinary shareholder's perspective, that is the real ownership question. VisionWave is not only putting stock on the table. It is also receiving an early path into the board, the committees, and the capital-allocation process before the final ownership endpoint is reached. So anyone asking who captures the value needs to look not only at the end-state cap table, but also at who sits in the boardroom, who receives stock directly, and who gets to shape how at least half of the company-level consideration is deployed.

Registration helps, but it does not solve the problem. VisionWave undertook to file a resale registration statement within ten business days after approval of the transaction and to keep it effective for at least two years, or until the shares can be sold freely. That improves the monetization path. It still does not turn VisionWave stock into free cash inside SaverOne, and it certainly does not change the fact that a large part of the package is either pre-committed to the new platform or transferred directly to management.

The Bottom Line

The VisionWave transaction does open real strategic value. It adds RF technology, a path toward a defense-facing pilot, and the possibility of turning SaverOne from a narrower transport-safety platform into the operating arm of a broader defense lane. That is not cosmetic. It is a real change in what the company may become.

But that value does not sit in one clean layer, and it certainly does not all sit with common shareholders. The consideration at the company level is outside stock, not cash. At least half of it is pre-committed to the RF platform. Up to another $3 million can go directly to management. And VisionWave receives a staged path into the board, the committees, and the budget process along the way. So the right sentence is not "the company opened $7 million of value." It is a new structure of control, capital, and incentives has been built, and only then will it become clear how much value remains for common shareholders.

The reasonable counter-thesis is that this is exactly the right design for a defense pivot. VisionWave supplies stock and technology, management gets equity that vests with milestones, and the company is forced to reinvest in the platform rather than burn the consideration on short runway. That is a legitimate argument. But it does not remove the central question, whether Milestone 1 and Milestone 2 will create enough operating value before the control path, the oversight path, and the management allocation outrun the value that becomes accessible to public shareholders.

So over the next 2-4 quarters, investors should spend less time on the headline of a "strategic partnership" and more time on three hard checkpoints: whether Milestone 1 really turns technical access into a fully operational license, whether the first pilot arrives as a binding operating event rather than a narrative marker, and whether new value that starts to form remains in the public-company layer faster than it is earmarked, allocated, or pulled into the new control structure.

Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.

The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.

The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.

Found an issue in this analysis?Editorial corrections and sharp feedback help keep the coverage honest.
Report a correction